Información de Biogen Inc, dividendo de Biogen Inc, actividades de los accionistas y más

Más Datos de Biogen Inc Compañía

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Información de Biogen Inc



Símbolo de cotizaciónBIIB

Nombre de la empresaBiogen Inc

Fecha de salida a bolsaSep 17, 1991

Director ejecutivoViehbacher (Christopher A)

Número de empleados7605

Tipo de seguridadOrdinary Share

Fin del año fiscalSep 17

Dirección225 Binney Street

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02142

Teléfono17814642000

Sitio Webhttps://www.biogen.com/

Símbolo de cotizaciónBIIB

Fecha de salida a bolsaSep 17, 1991

Director ejecutivoViehbacher (Christopher A)

Ejecutivos de Biogen Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

Mr. Jesus B. Mantas

Independent Director

8.42K

+28.15%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.04K

+12.73%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

5.88K

+59.46%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+43.29%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

Otro

3.25B

32.82%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

3.73B

37.67%

Rest of world

3.57B

36.11%

United states-Revenues from anti-CD20 therapeutic

1.86B

18.81%

Rest of World-Other revenues

732.90M

7.41%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

Otro

3.25B

32.82%

Estadísticas de accionistas

Actualizado: hace 15 horas

Accionistas

Tipos de accionistas

Accionistas

Proporción

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

Otro

67.39%

Accionistas

Proporción

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

Otro

67.39%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

66.96%

Investment Advisor/Hedge Fund

25.97%

Hedge Fund

6.52%

Pension Fund

3.17%

Research Firm

2.81%

Sovereign Wealth Fund

1.84%

Bank and Trust

1.76%

Individual Investor

0.20%

Family Office

0.16%

Participación institucional



Actualizado: jue., 9 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

2085

144.76M

98.05%

-3.98M

2025Q4

1994

139.65M

97.81%

+140.37K

2025Q3

2054

139.52M

98.56%

+3.73M

2025Q2

2076

135.78M

99.30%

-133.40K

2025Q1

2125

136.05M

101.20%

-12.08M

2024Q4

2114

138.28M

98.83%

+2.02M

2024Q3

2089

135.94M

98.13%

+100.43K

2024Q2

2100

135.44M

97.85%

-355.51K

2024Q1

2106

135.99M

97.60%

-5.88M

2023Q4

2136

135.17M

94.89%

+4.09M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

PRIMECAP Management Company

14.76M

10.06%

-196.70K

-1.32%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

8.73M

5.95%

+513.30K

+6.25%

Dec 31, 2025

Fidelity Management & Research Company LLC

7.97M

5.43%

+6.90M

+642.96%

Dec 31, 2025

State Street Investment Management (US)

7.16M

4.88%

-160.73K

-2.20%

Dec 31, 2025

Geode Capital Management, L.L.C.

4.20M

2.86%

+130.62K

+3.21%

Dec 31, 2025

Wellington Management Company, LLP

3.55M

2.42%

-695.24K

-16.37%

Dec 31, 2025

Point72 Asset Management, L.P.

2.81M

1.92%

-1.06M

-27.36%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

2.64M

1.8%

+374.66K

+16.55%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco Biotechnology & Genome ETF

5.49%

First Trust NASDAQ Pharmaceuticals ETF

4.45%

iShares Neuroscience and Healthcare ETF

4.25%

First Trust NYSE Arca Biotechnology Index Fund

3.53%

VanEck Biotech ETF

3.46%

Invesco Pharmaceuticals ETF

3.01%

iShares Health Innovation Active ETF

2.81%

First Trust Health Care Alphadex Fund

2.4%

ProShares Ultra Nasdaq Biotechnology

2.22%

Alger Russell Innovation ETF

2.21%

Invesco Biotechnology & Genome ETF

Proporción5.49%

First Trust NASDAQ Pharmaceuticals ETF

Proporción4.45%

iShares Neuroscience and Healthcare ETF

Proporción4.25%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.53%

VanEck Biotech ETF

Proporción3.46%

Invesco Pharmaceuticals ETF

Proporción3.01%

iShares Health Innovation Active ETF

Proporción2.81%

First Trust Health Care Alphadex Fund

Proporción2.4%

ProShares Ultra Nasdaq Biotechnology

Proporción2.22%

Alger Russell Innovation ETF

Proporción2.21%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos